Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-08-25
1991-08-06
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514212, 514319, 514625, 514630, 514653, A61K 3140, A61K 3155, A61K 31445, A61K 3116
Patent
active
050378481
ABSTRACT:
A compound and method are disclosed for reducing the effects of epilepsy, especially temporal lobe epilepsy. The treatment disclosed by the subject invention is provided by administering an aryl-cycloalkyl-alkanolamine substance having the general formula: ##STR1## The compounds procyclidine, biperiden, and trihexyphenidyl fall within this class of compounds. Although not previously recognized to be effective against epilepsy, all three representative compounds were tested against soman and pilocarpine, two cholinergic neurotoxins used in animal research on epilepsy. All three of those compounds were shown to be highly effective in providing protection against the seizures and neurological damage caused by cholinergic neurotoxins, even when administered only after the onset of convulsions.
REFERENCES:
patent: 4945097 (1990-07-01), Olney
Olney, J. W., "Excitatory Transmitters and Epilepsy-Related Brain Damage", Intl. Rev. Neurobiol., 27: 337-362 (1985).
Clifford, D. B., Olney, J. W., Maniotis, A., Collins, R. C. and Zorumski, C. F., "The Functional Anatomy and Pathology of Lithium-Pilocarpine and High-Dose Pilocarpine Seizures", Neurosci., 23: 953-968, (1987).
Olney, J. W., et al., "Anti-Parkinsonian Agents are Phencyclidine Agonists and N-methyl Aspartate Antagonists", Eur. J. Pharmacol., 142: 319-320, (1987).
Millichap, J. G., et al., "Anticonvulsant Activity of Antiparkinsonian Agents", Proc. Soc. Exp. Biol. Med., 127: 1187-1190 (1968).
Loscher, W., "Influence of Pharmacological Manipulation . . . on Seizure Behavior in the Mongolian Gerbil", J. Pharmacol. and Exp. Therapeutics, 233(1): 204-213 (1985).
Vernier, V. G., "Antiparkinsonism Drugs", Chapter 45 in Burger's Medicinal Chemistry, 4th Edition, edited by M. E. Wolff, (John Wiley & Sons, New York, 1981).
C. J. Vas et al., "EEG Activation by Procyclidine Hydrochloride in Temporal Lobe Epilepsy", Electroencephalography and Clinical Neurophysiology, 22: 395 (1967).
C. J. Vas et al., "Activation of the EEG by Procyclidine Hydrochloride in Temporal Lobe Epilepsy", Epilepsia, 8: 241-251 (1967).
C. Kamei et al., "Effects of Antiepileptics on Both Behavioral and Electrographic Seizure Patterns Induced by Maximal Electroshock in Rats", Epilepsia, 19: 625-636 (1978).
Gardner Diane
Waddell Frederick E.
Washington University
LandOfFree
Aryl-cycloalkyl-alkanolamines for treatment of epilepsy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl-cycloalkyl-alkanolamines for treatment of epilepsy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl-cycloalkyl-alkanolamines for treatment of epilepsy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1987378